pan-Canadian Pharmaceutical Alliance
Conducting collective expert-informed negotiations for drugs.
What's New at the pCPA
Effective May 10, 2024, Dominic Tan has assumed the responsibilities of CEO of the pCPA on an interim basis.
April 5, 2024 - Following consultations with stakeholders in the late summer and early fall of 2023, we have finalized the principles and conditions for the new pCPA Temporary Access Process (pTAP).
The pan-Canadian Pharmaceutical Alliance (pCPA) is an independent organization whose membership includes the provincial, territorial and federal governments. Member jurisdictions collaborate on a range of public drug plan initiatives to increase and manage access to clinically effective and affordable drug treatments.
One of the pCPA’s key roles is to conduct joint negotiations for brand name and generic drugs in Canada in order to achieve greater value for publicly funded drug programs and patients through its combined negotiating power. Its objectives are to:
- Increase access to clinically relevant and cost-effective treatments
- Achieve consistent and lower drug costs
- Improve consistency in funding decisions
- Reduce duplication and optimize resource utilization